

Resource Summary Report

Generated by [dkNET](#) on Sep 2, 2026

PE/Cyanine7 anti-mouse CD8a

RRID:AB_312760

Type: Antibody

Proper Citation

BioLegend Cat# 100721, RRID:AB_312760

Antibody Information

URL: http://antibodyregistry.org/AB_312760

Proper Citation: BioLegend Cat# 100721, RRID:AB_312760

Target Antigen: CD8alpha

Host Organism: rat

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: PE/Cyanine7 anti-mouse CD8a

Description: This monoclonal targets CD8alpha

Target Organism: mouse

Clone ID: Clone 53-6.7

Antibody ID: AB_312760

Vendor: BioLegend

Catalog Number: 100721

Alternative Catalog Numbers: 100722

Record Creation Time: 20231110T045028+0000

Record Last Update: 20260829T165711+0000

Ratings and Alerts

No rating or validation information has been found for PE/Cyanine7 anti-mouse CD8a.

No alerts have been found for PE/Cyanine7 anti-mouse CD8a.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Shalita R, et al. (2026) Localized PD-1 CAR T therapy reprograms neuroinflammation. Cell.

Hahm ER, et al. (2026) Oral Administration of Withaferin A Increases Infiltration of CD4+ Helper T Cells in a Mouse Model of Mammary Tumor. Journal of cancer prevention, 31(2), 91.

Chen S, et al. (2026) 16-h fasting optimizes cancer immunotherapy in mice and humans. Cell metabolism, 38(5), 944.

Zhang J, et al. (2026) Mrgpra2+ neutrophils integrate infection-derived signals to trigger NET-mediated antimicrobial defense in bone marrow. Cell reports, 45(7), 117579.

Gong F, et al. (2026) Trans-presentation of IL-6R? by macrophages drives colorectal cancer development. Cell reports, 45(7), 117549.

Sheban F, et al. (2025) ZEB2 is a master switch controlling the tumor-associated macrophage program. Cancer cell, 43(7), 1227.

Lecointre M, et al. (2025) HPV16-Expressing Tumors Release Multiple IL1 Ligands to Orchestrate Systemic Immunosuppression Whose Disruption Enables Efficacy of a Therapeutic Vaccine. Cancer discovery, 15(7), 1458.

Li D, et al. (2025) SOSTDC1 downregulation in CD4+ T cells confers protection against obesity-induced insulin resistance. Cell reports, 44(4), 115496.

Vrieling F, et al. (2025) Protocol for measuring cellular energetics through noncanonical amino acid tagging in human peripheral blood and murine tissue immune cells. STAR protocols, 6(4), 104134.

Coulibaly ASK, et al. (2025) Id2 levels determine the development of effector vs. exhausted tissue-resident memory CD8+ T cells during CNS chronic infection. Cell reports, 44(6), 115861.

Qian J, et al. (2025) A CXCR4 partial agonist improves immunotherapy by targeting immunosuppressive neutrophils and cancer-driven granulopoiesis. Cancer cell, 43(8),

1512.

Murphy MK, et al. (2025) The transcriptional repressor BLIMP1 enforces TCF-1-dependent and -independent restriction of the memory fate of CD8⁺ T cells. *Immunity*, 58(10), 2472.

Kandasamy M, et al. (2025) Glycogen synthase kinase-3 is essential for Treg development and function. *Cell reports*, 44(9), 116256.

Hyslop S, et al. (2025) CD7 regulates the persistence of terminally exhausted CD8⁺ T cells during chronic infection. *Cell reports*, 44(10), 116316.

Misel-Wuchter KM, et al. (2025) Developmental epigenetic programming by Tet1/3 determines peripheral CD8 T cell fate. *EMBO reports*, 26(10), 2494.

Frisch AT, et al. (2025) Redirecting glucose flux during in vitro expansion generates epigenetically and metabolically superior T cells for cancer immunotherapy. *Cell metabolism*, 37(4), 870.

Gao C, et al. (2025) Cancer vaccine from intracellularly gelated tumor cells functionalized with CD47 blockage and damage-associated molecular pattern exposure. *Cell reports. Medicine*, 6(5), 102092.

Galan-Cobo A, et al. (2025) KEAP1 and STK11/LKB1 alterations enhance vulnerability to ATR inhibition in KRAS mutant non-small cell lung cancer. *Cancer cell*, 43(8), 1530.

Lang PA, et al. (2025) Optimized arenaviruses with tumor-tropic mutations promote safe anti-tumor efficacy via sustainable immune modulatory properties. *Cell reports. Medicine*, 6(10), 102411.

Fang X, et al. (2025) The m6A reader HNRNPC is a key regulator in DSS-induced colitis by modulating macrophage phenotype. *iScience*, 28(3), 111812.